Skip to main content

Table 2 Subgroup analysis

From: Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials

  MACE Cardiovascular death Major bleeding Net clinical events
  RR(95% CI) I2 (%) p RR(95% CI) I2 (%) p RR(95% CI) I2 (%) p RR(95% CI) I2 (%) p
Strategies to overcome HPR   0.02    0.26    0.60    <0.001
Repeated LD 0.06(0.01–0.29) 0 <0.001 0.15(0.02–1.18) 0 0.07 1.02(0.21–5.02) 0 0.98 0.14(0.05–0.38) 0 <0.001
Increased MD 0.56(0.39–0.96) 66 0.003 0.41(0.20–0.84) 0 0.01 0.69(0.38–1.25) 0 0.22 0.59(0.44–0.81) 10 0.001
Switch to prasugrel 0.77(0.28–2.15) 49 0.62     1.01(0.49–2.11) 5 0.97 1.00(0.81–1.24) 0 1.00
Intervention duration   <0.001    0.06    0.26    <0.001
≤1 month 0.16(0.07–0.37) 0 <0.001 0.17(0.04–0.75) 0 0.02 1.51(0.43–5.34) 0 0.52 0.21(0.11–0.42) 0 <0.001
>1 month 0.81(0.58–1.14) 65 0.23 0.75(0.45–1.25) 6 0.27 0.71(0.51–0.99) 0 0.05 0.93(0.75–1.14) 54 0.47
Follow up duration   0.03    0.11    0.91    <0.001
1 month 0.09(0.02–0.40) 0 0.001 0.15(0.02–1.18) 0 0.07 1.02(0.21–5.02) 0 0.98 0.15(0.06–0.38) 0 <0.001
6 months 0.48(0.21–1.11) 38 0.09 0.30(0.09–1.00) 0 0.05 0.77(0.44–1.36) 11 0.38 0.72(0.49–1.08) 2 0.11
12 months 0.73(0.46–1.14) 75 0.16 0.84(0.49–1.15) 0 0.53 0.72(0.49–1.08) 0 0.11 0.93(0.72–1.21) 71 0.60
Platelet function device   0.05    0.27    0.72    <0.001
VerifyNow 0.94(0.70–1.27) 37 0.69 0.69(0.37–1.32) 39 0.26 0.76(0.54–1.05) 0 0.10 0.98(0.82–1.16) 26 0.79
VASP 0.20(0.05–0.91) 58 0.04 0.38(0.16–0.89) 0 0.03 1.02(0.21–5.02) 0 0.98 0.27(0.12–0.59) 38 0.001